Treatment 5 min
Metastatic prostate cancer: hormone therapy and what comes next
How prostate cancer with metastases is treated: hormone therapy, how it is intensified, what castration resistance means and which options follow.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 23 October 2026
In metastatic prostate cancer the basis of treatment is hormone therapy: lowering the male hormones the tumour relies on. Today it is often intensified with additional drugs rather than given alone.
First stage
- Androgen deprivation therapy (GnRH agonists or antagonists, or orchiectomy) lowers testosterone.
- Intensification: newer hormonal drugs (for example abiraterone, enzalutamide, apalutamide, darolutamide) or docetaxel chemotherapy are added, depending on indications and the patient’s condition.
- Monitoring: PSA, imaging, symptoms, bone health and the risks of hormone therapy.
What comes next if the disease progresses
When the disease grows despite low testosterone, this is called castration resistance. Then changing the hormonal drug, chemotherapy, radioligand therapy (including based on PSMA-PET) and, with BRCA and some other mutations, PARP inhibitors are discussed. Availability depends on the country and clinic.
Side effects of hormone therapy and how to live with them
Lowering testosterone affects the whole body, so it is worth knowing in advance.
- Hot flushes, tiredness, reduced libido and erectile dysfunction.
- Bone loss: calcium, vitamin D and, when indicated, bone-protecting drugs and density monitoring are discussed.
- Metabolism and heart: weight gain, rising sugar and cholesterol are possible; movement, diet and regular tests help.
- Mood and sleep: tell the doctor about depression or anxiety, it can be treated. Intensifying drugs (abiraterone, enzalutamide and others) have their own features: blood pressure, liver, seizures, drug interactions. Agree all medicines with your oncologist.
The basis of treatment and what is added
The basis of treatment of hormone-sensitive metastatic prostate cancer is lowering testosterone (androgen deprivation): GnRH analogue injections or surgical castration. Today treatment is often intensified from the start: drugs that block androgen action are added and, in some patients, docetaxel chemotherapy. The choice depends on the volume of metastases, general condition and other illnesses.
The effect is judged by PSA, symptoms and scans. If PSA rises again with low testosterone, this is called castration-resistant disease and the plan is reviewed.
What to do if the disease becomes resistant
Resistance to hormone therapy does not mean there are no options. Discussed are:
- Other new-generation hormonal drugs, if not yet used.
- Chemotherapy (docetaxel, then cabazitaxel).
- Radiopharmaceuticals for bone metastases (radium-223, lutetium-PSMA in suitable cases).
- PARP inhibitors for mutations in DNA repair genes such as BRCA; hence molecular tumour testing or germline testing is useful.
- Bone protection and pain treatment. PSMA PET-CT gives a more precise picture of spread than conventional methods and affects the choice of tactics.
What to check before deciding
- Whether the diagnosis is confirmed by pathology and whether the tumour subtype is known.
- What the volume of metastases is: small or large, and whether there are visceral lesions.
- Whether PSMA PET-CT and molecular tests were done.
- Which drugs were already used and in what order.
- Whether there is a threat of bone complications (fractures, spinal cord compression).
- How treatment will affect the heart, blood pressure and metabolism. If only one option is offered, a second opinion is useful: the order of drugs affects later possibilities.
Modern diagnostics: PSMA PET and molecular tests
PSMA PET-CT is more sensitive than conventional CT and bone scan and shows lesions other methods miss. It can change the stage and tactics, for example reveal oligometastatic disease, where local treatment is added. The method is not available everywhere and is not always reimbursed, but it is worth discussing with the doctor.
Molecular tests (BRCA1/2, ATM and other DNA repair genes, MSI) show whether PARP inhibitors or immunotherapy will suit. Germline testing is important for relatives too: men with BRCA2 have a higher prostate cancer risk, and women in the family a higher risk of breast and ovarian cancer.
Bones, pain and quality of life
Bone metastases occur in most patients with this disease and many symptoms depend on them.
- Pain is treated with drugs and palliative radiotherapy, often a single session is enough.
- Bone protection: denosumab or zoledronic acid reduce fracture risk; dental clearance is needed before them.
- Spinal cord compression (leg weakness, urinary problems) needs urgent help.
- Radiopharmaceuticals (radium-223) are used for bone metastases without visceral ones.
- Physical activity and nutrition help keep muscle during hormone therapy. Quality of life should be discussed as seriously as PSA values.
What to ask your doctor
- Which stage of the disease are you at and why was this combination chosen?
- Has genetic testing been done?
- How often should PSA be checked and when are scans needed?
- How can bones and heart be protected on hormone therapy?
If you need to check the regimen or choose the next step, I can review your documents at a consultation.
Sources
Frequently asked questions
This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.
